Ensysce Biosciences Financials

ENSC Stock  USD 5.34  0.05  0.93%   
Based on the key indicators related to Ensysce Biosciences' liquidity, profitability, solvency, and operating efficiency, Ensysce Biosciences may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At present, Ensysce Biosciences' Common Stock Shares Outstanding is projected to decrease significantly based on the last few years of reporting. The current year's Capital Surpluse is expected to grow to about 129.5 M, whereas Total Assets are forecasted to decline to about 2.3 M. Key indicators impacting Ensysce Biosciences' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio0.750.79
Notably Down
Slightly volatile
Investors should never underestimate Ensysce Biosciences' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Ensysce Biosciences' cash flow, debt, and profitability to make informed and accurate decisions about investing in Ensysce Biosciences.

Cash And Equivalents

2.69 Million

3.1M2.8M2.7M100%
  
Understanding current and past Ensysce Biosciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Ensysce Biosciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Ensysce Biosciences' assets may result in an increase in income on the income statement.
Please note, the presentation of Ensysce Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ensysce Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ensysce Biosciences' management manipulating its earnings.

Ensysce Biosciences Stock Summary

Ensysce Biosciences competes with Zura Bio, Phio Pharmaceuticals, Sonnet Biotherapeutics, 180 Life, and Cardio Diagnostics. Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614 PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse and PF26810, an extended-release prodrug of methadone for opioid use disorder. Ensysce Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS2936021086
CUSIP52539T107 293602108 293602405 293602207 293602504
LocationCalifornia; U.S.A
Business Address7946 Ivanhoe Avenue,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.ensysce.com
Phone858 263 4196
CurrencyUSD - US Dollar

Ensysce Biosciences Key Financial Ratios

Ensysce Biosciences Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets351.8K16.4M5.9M2.7M2.4M2.3M
Retained Earnings(56.0M)(85.8M)(110.9M)(121.6M)(109.4M)(103.9M)
Cash194.2K12.3M3.1M1.1M1.3M1.2M
Other Assets5K3.8K754.8K585.9K527.3K500.9K
Long Term Debt Total566.3K791.3K4.4M140.2K161.2K153.1K
Capital Surpluse2.9M2.5M78.0M107.2M123.3M129.5M
Total Liab7.0M24.6M9.9M3.4M3.9M3.7M
Total Current Assets347.9K15.7M5.3M2.3M2.1M2.0M
Short Term Debt4.3M12.7M4.3M854.7K982.9K933.8K
Common Stock1.6K2.5K642.0315.0283.5269.33
Other Current Liab856.0K3.4M2.3M542.3K623.6K592.4K
Net Debt4.1M483.4K1.3M(268.9K)(309.2K)(293.8K)
Accounts Payable1.7M301.1K2.9M1.9M2.2M1.4M
Other Current Assets153.7K3.4M2.2M1.1M1.2M1.3M

Ensysce Biosciences Key Income Statement Accounts

202020212022202320242025 (projected)
Interest Income4.2M939.7K622K109.5K98.6K93.6K
Interest Expense995.5K1.3M109.5K353.9K407.0K432.8K
Total Revenue3.9M3.5M2.5M2.2M2.6M2.2M
Operating Income(1.6M)(19.9M)(24.2M)(10.7M)(9.6M)(10.1M)
Income Before Tax(160.9K)(29.1M)(24.2M)(10.6M)(9.6M)(10.0M)
Net Income(938.7K)(29.1M)(25.0M)(10.6M)(9.6M)(10.0M)
Gross Profit2.6M3.5M(17.3M)(5.4M)(4.8M)(5.1M)
Ebit(1.6M)(19.9M)(24.2M)(10.7M)(9.6M)(10.1M)
Ebitda(1.6M)(19.9M)(24.2M)(10.7M)(9.6M)(10.1M)
Cost Of Revenue1.4M151.019.8M7.6M8.7M6.2M
Income Tax Expense777.9K(151.0)753.9K(264.0)(303.6)(288.42)
Research Development4.4M4.7M19.8M7.6M8.7M8.8M

Ensysce Biosciences Key Cash Accounts

202020212022202320242025 (projected)
Change In Cash(147.3K)12.1M(9.1M)(2.0M)(1.8M)(1.7M)
Free Cash Flow(1.2M)(8.2M)(17.9M)(10.8M)(9.7M)(9.2M)
Other Non Cash Items997.5K7.5M(233.4K)(85.8K)(77.2K)(73.3K)
Net Income(160.9K)(29.1M)(24.2M)(10.6M)(9.6M)(10.0M)
End Period Cash Flow194.2K12.3M3.1M1.1M1.3M1.2M
Change To Inventory(173.6K)441.7K(164.9K)(1.1M)(1.3M)(1.4M)

Ensysce Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Ensysce Biosciences's current stock value. Our valuation model uses many indicators to compare Ensysce Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ensysce Biosciences competition to find correlations between indicators driving Ensysce Biosciences's intrinsic value. More Info.
JavaScript chart by amCharts 3.21.15KPRXZURAVRAXBDRXBWVALLRENSC -0.7-0.6-0.5-0.4-0.3-0.2-0.100.1 -2.5-2.0-1.5-1.0-0.50
Ensysce Biosciences is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At present, Ensysce Biosciences' Return On Equity is projected to increase significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ensysce Biosciences' earnings, one of the primary drivers of an investment's value.

Ensysce Biosciences Systematic Risk

Ensysce Biosciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Ensysce Biosciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Ensysce Biosciences correlated with the market. If Beta is less than 0 Ensysce Biosciences generally moves in the opposite direction as compared to the market. If Ensysce Biosciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Ensysce Biosciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Ensysce Biosciences is generally in the same direction as the market. If Beta > 1 Ensysce Biosciences moves generally in the same direction as, but more than the movement of the benchmark.
JavaScript chart by amCharts 3.21.15Dec2025FebJan 20Jan 27FebFeb 10Feb 17Feb 245.05.56.06.57.07.58.0 50K100K150K200K250K300K350K400K 00.010.020.030.040.050.06 42.5K43K43.5K44K44.5K Show all
JavaScript chart by amCharts 3.21.15Ensysce Biosciences Volume Ensysce Biosciences Closing Prices Dow Jones Industrial Closing Prices - Benchmark Ensysce Biosciences Beta
Today, most investors in Ensysce Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Ensysce Biosciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Ensysce Biosciences growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.03

At present, Ensysce Biosciences' Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.

Ensysce Biosciences February 27, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Ensysce Biosciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Ensysce Biosciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Ensysce Biosciences based on widely used predictive technical indicators. In general, we focus on analyzing Ensysce Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Ensysce Biosciences's daily price indicators and compare them against related drivers.

Complementary Tools for Ensysce Stock analysis

When running Ensysce Biosciences' price analysis, check to measure Ensysce Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ensysce Biosciences is operating at the current time. Most of Ensysce Biosciences' value examination focuses on studying past and present price action to predict the probability of Ensysce Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ensysce Biosciences' price. Additionally, you may evaluate how the addition of Ensysce Biosciences to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Bonds Directory
Find actively traded corporate debentures issued by US companies
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges